Who
Jeffrey G. Lamothe
President and CEO
Company insider
Files Form 4 as: President and CEO, Aptevo Therapeutics.
In numbers
- Trades disclosed
- 82
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Aug 2016
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —961 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —961 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —961 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —961 | filing |
| 6 Aug 2025filed 8 Aug 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,300 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —5 | filing |
| 3 Mar 2025filed 4 Mar 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —2 | filing |
| 2 Mar 2025filed 4 Mar 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3 at $0.00 | filing |
| 2 Mar 2025filed 4 Mar 2025 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3 | filing |
| 8 Aug 2024filed 9 Aug 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —42 at $0.00 | filing |
| 8 Aug 2024filed 9 Aug 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —272 at $0.00 | filing |
| 8 Aug 2024filed 9 Aug 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —42 | filing |
| 8 Aug 2024filed 9 Aug 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —272 | filing |
| 17 Jul 2024filed 19 Jul 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,825 at $0.00 | filing |
| 3 Mar 2024filed 5 Mar 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,667 at $0.00 | filing |
| 3 Mar 2024filed 5 Mar 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,667 | filing |
| 2 Mar 2024filed 5 Mar 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 2 Mar 2024filed 5 Mar 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,500 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.